Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 496 results for 2011

  1. HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (HTG429)

    Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.

  2. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

    Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.

  3. Psychosis and schizophrenia in children and young people: recognition and management (CG155)

    This guideline covers recognising and managing psychosis and schizophrenia in children and young people. It aims to improve early recognition of psychosis and schizophrenia so that children and young people can be offered the treatment and care they need to live with the condition.

  4. Shiley Endotracheal Tube with TaperGuard Cuff for intensive care patients at risk of ventilator‑associated pneumonia (MIB22)

    NICE has developed a medtech innovation briefing (MIB) on the Shiley Endotracheal Tube with TaperGuard Cuff .

  5. MiraQ for assessing graft flow during coronary artery bypass graft surgery (HTG275)

    Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.

  6. Executive team

    Day-to-day decision making is the responsibility of NICE's executive team.

  7. The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)

    NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy

  8. Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

    Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

  9. What proxy outcome measures are suitable for studies of the primary prevention of skin cancer?

    Skin cancer prevention Number PH32 Date issued January 2011 Other details Is this a recommendation for the use

  10. Clinical trials should be conducted comparing ticagrelor with prasugrel in people with acute coronary syndromes (ACS).

    coronary syndromes Number TA236 Date issued October 2011 Other details Is this a recommendation for the use

  11. Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers (HTG355)

    Evidence-based recommendations on Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers.

  12. Further research into the comparative efficacy and safety of different surgical and ablative treatments would be useful.

    cryotherapy for renal cancer Number IPG405 Date issued August 2011 Other details Is this a recommendation for the use

  13. Further research into whether ticagrelor is particularly beneficial in any clinical or biological subgroups would be useful.

    coronary syndromes Number TA236 Date issued October 2011 Other details Is this a recommendation for the use

  14. What risk factors predict the onset of substance misuse in young people with psychosis?

    in healthcare settings Number CG120 Date issued March 2011 Other details Is this a recommendation for the use

  15. Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical of UK clinical practice would be useful to determine the size of the effect of mifamurtide.

    treatment of osteosarcoma Number TA235 Date issued October 2011 Other details Is this a recommendation for the use